Gojo, Ivana <br/><br/>
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Apr 2013 
 - 1838-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-12-3165  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B--genetics<br/>ATP Binding Cassette Transporter, Subfamily G, Member 2<br/>ATP-Binding Cassette Transporters--genetics<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cytarabine--administration & dosage<br/>Etoposide--administration & dosage<br/>Female<br/>Gene Expression Regulation, Leukemic--drug effects<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Karyotype<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Proteins--genetics<br/>Recurrence<br/>Translational Research, Biomedical<br/>Treatment Outcome<br/>Tumor Necrosis Factor Decoy Receptors--genetics<br/>Vorinostat<br/>Young Adult